BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations For Temporary Disruption Of Operations.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Temporary Disruption of operations at Manufacturing facility situated at Grantlyon, Chennai. BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window
Intimation for Closure of Trading Window. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We hereby enclose the Newspaper Publication for the Audited Financial Results for the Quarter ended March 31, 2024 published in "Business Standard" (English) and "Makkal Kural" (Tamil) on May 31, 2024. BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Reg.24(A)-Annual Secretarial Compliance
We are herewith filing the Annual Secretarial Compliance Report for the financial year ended March 31, 2024. BAFNA PHARMACEUTICALS LTD. - 532989 - Appointment of Company Secretary and Compliance Officer
We hereby inform that the Board of Directors in their meeting held on May 29, 2024 has appointed Mr. A Mohanachandran as the Company Secretary & Compliance officer of the Company w.e.f May 29, 2024. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 29/05/2024.
The Board of Directors in the meeting held on 29/05/2019 has inter-alia (i) approved the audited financial results of the Company for the quarter & year ended March 31, 2024; (ii) ii). Appointment of Mr. A. Mohanachandran, as the Company Secretary & Compliance Officer of the Company with effect from May 29, 2024 BAFNA PHARMACEUTICALS LTD. - 532989 - Audited Financial Results Of The Company For The Quarter & Year Ended 31/03/2024
We are herewith submitting the Audited Financial Results for the Quarter & Year ended 31/03/2024 BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2024
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 ,inter alia, to consider and approve Consideration and Approval of the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2024. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement Regarding Inauguration Of New Quality Control Laboratory Of Company
We are delighted to announce the inauguration of new State-of-the-Art Quality Control Laboratory of the Company. BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Period Ended 31St March, 2024
We are herewith submitting the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period ended 31st March, 2024.